drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Gene-modified autologous T cells engineered with a chimeric antigen receptor targeting BCMA and FcRL5 to mediate targeted cytotoxicity against multiple myeloma cells; dual targeting aims to reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Chimeric Antigen Receptor-Modified
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor that recognizes BCMA and FcRL5 on multiple myeloma cells. CAR engagement triggers TCR signaling (CD3ΞΆ with costimulatory domains), leading to targeted T-cell activation, proliferation, and cytotoxic killing of BCMA+/FcRL5+ tumor cells. Dual targeting is intended to reduce antigen escape and enhance tumor clearance.
drug_name
Autologous anti-BCMA/FcRL5 CAR T cells
nct_id_drug_ref
NCT06759181